Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (ASX:PBT) covers the month of December 2017. The report discloses a Change of Director's Interest Notice under ASX Listing Rule 3.19A.2 regarding Mr. Peter Marks, a director of the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a director's securities transaction rather than a financial performance report.
Material Changes
On December 19, 2017, Director Mr. Peter Marks exercised options under the company's employer share option plan. The specific changes in holdings were:
- Shares: No change in direct or indirect shareholdings (remained at 43,111 indirect shares).
- Options: Acquired 250,000 unlisted options, increasing his total option holding from 1,000,000 to 1,250,000.
- Consideration: The value is referenced in the Explanatory Memorandum accompanying the 2017 Notice of Annual General Meeting, but no specific monetary figure is provided in this text.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The transaction was not conducted during a closed period, and no prior written clearance was required.
Investor Verification Checklist
- Verify the specific exercise price and total consideration paid for the 250,000 options by reviewing the 2017 Notice of Annual General Meeting Explanatory Memorandum.
- Confirm the vesting schedule and expiry dates for the newly acquired unlisted options.
- Review the company's latest financial statements (Form 20-F) for actual revenue and cash flow data, as this 6-K does not contain financial metrics.